https://www.live-feeds.com/feed/merck-sees-pivotal-victory-for-3b-eye-disease-prospectContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/merck-sees-pivotal-victory-for-3b-eye-disease-prospecthttps://www.live-feeds.com/feed/merck-sees-pivotal-victory-for-3b-eye-disease-prospect#u85642Sat, 26 Sep 2026 23:46:06 +0000Merck's Remigromig met its primary endpoint in the pivotal Phase 2b/3 BRUNELLO study for adults with diabetic macular edema. The tri-specific agonist of the Wingless-related Integration Site (Wnt) pathway proved noninferior to ranibizumab. This result marks Merck's first success in its return to ophthalmology for a prospect with a projected $3 billion value. While the drug achieved its trial goal, reports indicate that safety concerns have emerged during the study.Why it mattersDiabetic macular edema is a complication of diabetes that affects vision. Merck is utilizing a Wnt pathway